Last reviewed 01/2018

Omapatrilat inhibits:

  • angiotensinogen converting enzyme, resulting in reduced vasoconstriction and renin activation
  • neutral endopeptidas,e resulting in elevated vasodilatory peptide concentrations

Omapatrilat was compared to lisinopril in 573 patients with NYHA grade II-IV heart failure. The patients had all required ACE inhibitor therapy prior to the trial.

Target doses were:

  • 40 mg omapatrilat per day
  • 20 mg lisinopril per day

Follow-up was 24 weeks.

The primary endpoint was exercise tolerance measured by a treadmill test at 12 weeks. Secondary endpoints included death, admission or discontinuation of treatment because of worsening heart failure.


  • (1) Rouleau, JL, Pfeffer , MA. et al. (2000). Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet, 356, 615-20.